Back to resultsAMG 714 Expanded Access Program
Primary Purpose
Celiac Disease
Status
Available
Phase
Locations
Study Type
Expanded Access
Intervention
AMG 714
Sponsored by
About this trial
This is an expanded access trial for Celiac Disease focused on measuring Refractory Celiac Disease Type II
Eligibility Criteria
Inclusion Criteria:
-
Exclusion Criteria:
-
Sites / Locations
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03439475
Brief Title
AMG 714 Expanded Access Program
Study Type
Expanded Access
2. Study Status
Record Verification Date
December 2022
Overall Recruitment Status
Available
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Amgen
4. Oversight
5. Study Description
Brief Summary
Expanded access requests for AMG 714 may be considered for adult patients with biopsy proven Refractory Celiac Disease Type II who have failed all available treatment options and do not have EATL. To request access, use Responsible Party contact information provided in this record.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Celiac Disease
Keywords
Refractory Celiac Disease Type II
7. Study Design
8. Arms, Groups, and Interventions
Intervention Type
Biological
Intervention Name(s)
AMG 714
10. Eligibility
Minimum Age & Unit of Time
18 Years
Eligibility Criteria
Inclusion Criteria:
-
Exclusion Criteria:
-
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Amgen Call Center
Phone
866-572-6436
Email
medinfo@amgen.com
12. IPD Sharing Statement
Learn more about this trial
AMG 714 Expanded Access Program
We'll reach out to this number within 24 hrs